Explore By Subject Area   
Return Home
Menu

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

Engineering advancements in T cell manufacturing can lead to reduced associated production costs for CAR T cell therapies, enabling broader access and scalability for patient benefit.

July 25, 2025
Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

Summary:
Accessibility to CAR-T is limited by traditional manufacturing, with its associated challenges and high cost. Moffitt Cancer Center's Chief BioEngineering Officer, Dr Greg Sawyer, highlights Moffitt's progress in enhancing T cell potency and boosting efficacy through engineering strategies. Dr Sawyer also discusses assays enabling precise assessment of T cell potency and developments in manufacturing, and the resulting impact on scalability and efficiency. 

This presentation comes from the March 2025 Immuno-Oncology 360º Summit. For more information, go to IO360summit.com. 

In this podcast

Featured Podcasts

Upcoming Conferences

Featured Editorial

Featured Videos & Webcasts

Related Podcasts

View All
Stanford's Dr Crystal Mackall on CAR T for Solid Tumors and Cell Therapy's Future, from IO360º 2025
Stanford's Dr Crystal Mackall on CAR T for Solid Tumors and Cell Therapy's Future, from IO360º 2025
Innovations in Manufacturing to Make CAR-T More Accessible and Affordable
Innovations in Manufacturing to Make CAR-T More Accessible and Affordable
2025 Biotech Markets & Immuno-Oncology Outlook
2025 Biotech Markets & Immuno-Oncology Outlook
Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability
Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.